Samantha T. Reyes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samantha T. Reyes has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Corinne Beinat
Stanford University
37 shared publications Israt S. Alam
Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, USA
36 shared publications- Andrei Iagaru
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA
35 shared publications Bin Shen
35 shared publicationsChirag B. Patel
35 shared publications- Daniel Dan Liu
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA
35 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A radiolabeled dendrimer non-invasively identifies and tracks innate immune cell activation in a mouse model of experimental autoimmune encephalomyelitis
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by infiltration of activated innate immune cells into the central nervous system (CNS). Current imaging approaches for diagnosing and monitoring disease progression rely on structural lesions and cannot directly assess innate immune activity. Here, we describe a dendrimer positron emission tomography (PET) tracer, 18F-flurimedrimer (18F-FMD), for non-invasive, longitudinal tracking of activated myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) murine model, 18F-FMD specifically detects myeloid activation at presymptomatic and symptomatic stages, with PET signal correlating with disease severity. Moreover, 18F-FMD sensitively captures therapeutic response to fingolimod (FTY720) and a CSF1R dendranib (H74DS3M8), both of which suppress immune cell activation and attenuate disease severity. These findings highlight the potential of 18F-FMD PET for specific, real-time monitoring of innate immune responses, and the applicability of the dendrimer in clinical settings for monitoring therapeutic efficacy, advancing the development of personalized, myeloid-targeted strategies for MS.
- 30 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA radiolabeled dendrimer non-invasively identifies and tracks innate immune cell activation in a mouse model of experimental autoimmune encephalomyelitis
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by infiltration of activated innate immune cells into the central nervous system (CNS). Current imaging approaches for diagnosing and monitoring disease progression rely on structural lesions and cannot directly assess innate immune activity. Here, we describe a dendrimer positron emission tomography (PET) tracer, 18F-flurimedrimer (18F-FMD), for non-invasive, longitudinal tracking of activated myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) murine model, 18F-FMD specifically detects myeloid activation at presymptomatic and symptomatic stages, with PET signal correlating with disease severity. Moreover, 18F-FMD sensitively captures therapeutic response to fingolimod (FTY720) and a CSF1R dendranib (H74DS3M8), both of which suppress immune cell activation and attenuate disease severity. These findings highlight the potential of 18F-FMD PET for specific, real-time monitoring of innate immune responses, and the applicability of the dendrimer in clinical settings for monitoring therapeutic efficacy, advancing the development of personalized, myeloid-targeted strategies for MS.
- Open Access
- 6 February 2025
- Published by Springer Nature in Research Square
Radiolabeled dendrimer non-invasively tracks innate immune activation in multiple sclerosis mice after immunomodulatory therapy
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by immune cell infiltration into the central nervous system (CNS). Despite the critical role of immune cells in MS initiation and progression, current standard of care imaging techniques rely on structural lesion assessments, often resulting in misdiagnoses and inaccurate disease staging. Here we describe a novel dendrimer positron emission tomography (PET) tracer, 18 F-flurimedrimer ( 18 F-FMD), for non-invasive detection and tracking of activated myeloid cells–key immune players in MS. Using an experimental autoimmune encephalomyelitis (EAE) murine model of MS, we demonstrate the ability of 18 F-FMD to specifically detect these cells at both presymptomatic and symptomatic stages, with signal intensity correlating with disease severity. We illustrate that 18 F-FMD can also accurately monitor the immunomodulatory effects of Food and Drug Administration (FDA)-approved disease-modifying MS drug fingolimod (FTY720) and a novel CSF1R dendranib (H74DS3M8), both of which reduced immune cell activation and halted disease progression. These findings highlight the potential of 18 F-FMD PET for early MS diagnosis and as a generalizable approach for real-time monitoring of therapeutic responses across various mechanisms. Since we have translated 18 F-FMD for clinical imaging, it has the potential to revolutionize patient stratification in clinical trials and optimize treatments, making precision medicine a reality for MS patients.
- 6 February 2025
- Published by Springer Nature in Research Square
Open AccessRadiolabeled dendrimer non-invasively tracks innate immune activation in multiple sclerosis mice after immunomodulatory therapy
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by immune cell infiltration into the central nervous system (CNS). Despite the critical role of immune cells in MS initiation and progression, current standard of care imaging techniques rely on structural lesion assessments, often resulting in misdiagnoses and inaccurate disease staging. Here we describe a novel dendrimer positron emission tomography (PET) tracer, 18 F-flurimedrimer ( 18 F-FMD), for non-invasive detection and tracking of activated myeloid cells–key immune players in MS. Using an experimental autoimmune encephalomyelitis (EAE) murine model of MS, we demonstrate the ability of 18 F-FMD to specifically detect these cells at both presymptomatic and symptomatic stages, with signal intensity correlating with disease severity. We illustrate that 18 F-FMD can also accurately monitor the immunomodulatory effects of Food and Drug Administration (FDA)-approved disease-modifying MS drug fingolimod (FTY720) and a novel CSF1R dendranib (H74DS3M8), both of which reduced immune cell activation and halted disease progression. These findings highlight the potential of 18 F-FMD PET for early MS diagnosis and as a generalizable approach for real-time monitoring of therapeutic responses across various mechanisms. Since we have translated 18 F-FMD for clinical imaging, it has the potential to revolutionize patient stratification in clinical trials and optimize treatments, making precision medicine a reality for MS patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
[18F]DASA-23 administered activity in brain tumor patients
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
[18F]DASA-23 administered activity in brain tumor patients
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Hematology laboratory testing results of patients imaged with [18F]DASA-23
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Hematology laboratory testing results of patients imaged with [18F]DASA-23
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Blood chemistry laboratory testing results of the patients imaged with [18F]DASA-23
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Blood chemistry laboratory testing results of the patients imaged with [18F]DASA-23
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Vital signs of the patients administered with [18F]DASA-23
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Vital signs of the patients administered with [18F]DASA-23
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Clinical Characteristics of patients imaged with [18F]DASA-23
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Clinical Characteristics of patients imaged with [18F]DASA-23